BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking

A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.